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potential for a CHIK virus pandemic. Efforts to monitor the
disease will only provide minimal warning in a global soci-
ety, and steps must be taken to prevent the morbidity and
mortality associated with a possible pandemic. There is no
speciﬁc treatment for Chikungunya virus and there is no
vaccine currently available. We propose a novel consensus-
based approach to vaccine development, employing a DNA
vaccine strategy that can provide more highly cross-reactive
cellular immunity against CHIK virus. The vaccine cassette
was designed based on Capsid (Cap) and Envelope (E1)
speciﬁc consensus sequences with several modiﬁcations,
including codon optimization, RNA optimization, the addi-
tion of a Kozak sequence, and a substituted immunoglobulin
E leader sequence. The expression of Cap and envelope
E1 was evaluated using T7-coupled transcription/translation
and immuno blot analysis. A recently developed, adap-
tive constant-current electroporation technique was used to
immunize mice (both Balb/C & C57BL/6 mice strain) with an
intramuscular injection of plasmid coding for the CHICK-Cap
and E1. We show such constructs can induce strong cellular
immunity against CHIK-Cap and E1 antigens. The analysis
of speciﬁc antibody responses suggested that CHIK-E1 could
induce a strong E1 speciﬁc antibody response. Epitope map-
ping results indicated that there is an increase in the breadth
and magnitude of cross-reactive cellular responses induced
by both the Capsid and Envelope immunogen. These prop-
erties suggest that such a consensus immunogen deserves
further examination for its potential to serve as a component
antigen in a CHIK vaccine cocktail.
doi:10.1016/j.ijid.2008.05.021
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Post-Exposure Vaccination with a Highly Attenuated Vac-
cinia Vaccine, LC16m8, for Protection of Nonhuman
Primates from Monkeypox
M. Saijo1,∗, Y. Ami1, Y. Suzaki1, N. Nagata1, H. Hasegawa1,
M. Ogata1, S. Fukushi1, T. Mizutani1, I. Iizuka1, I. Kurane2,
T. Kurata1, S. Morikawa1
1 National Institute of Infectious Diseases, Tokyo, Japan
2 National Institute of Infectious Diseases (Musashimu-
rayama), Musashimurayama, Japan
Introduction: A highly attenuated smallpox vaccine,
LC16m8, is generated from parent strain, vaccinia virus Lis-
ter, by passages of Lister in primary rabbit kidney cells at a
temperature of 30 ◦C. LC16m8 lacks expression of the full-
length B5R membrane protein, one of the most important
viral membrane proteins for induction of immune response
to vaccinia virus, due to a frameshift mutation in the gene.
A single vaccination with LC16m8 protects non-human pri-
mates (NHPs) from monkeypox, monkeypox virus infection.
In the present study, the efﬁcacy of LC16m8 as a thera-
peutic vaccine was evaluated in protection of NHPs from
monkeypox.
Materials and Methods: Twenty-two NHPs (Macaca fasci-
cularis) were used. The NHPs were immunized with LC16m8
or mock followed by subcutaneous inoculation of monkey-
pox Zr-599. Three were mock-immunized and infected with
the virus. Three were infected with the virus and then immu-
nized with LC16m8. Three, 3, and 5 NHPs were infected with
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he virus 3, 7, and 14—24 days after vaccination, respec-
ively. Clinical manifestations weremonitored. Viremia level
nd antibody response were determined by the quantita-
ive real-time PCR and IgG-ELISA, respectively. Pathological
xamination was carried out in these subjects.
Results: Post-exposure vaccination with LC16m8 for
HPs, which were infected with monkeypox virus, improved
he clinical manifestation of monkeypox, while all the naive
ubjects were nearly lethal. Vaccination with LC16m8 7 days
efore monkeypox virus challenge completely protected
HPs from monkeypox. Viremia level in the post-exposure
accinated subjects was signiﬁcantly lower than that in the
aive subjects.
Discussion: LC16m8 has been re-produced and stockpiled
n Japan for the possible threat of bioterrorism with variola
irus as a bioweapon. Based on these results, it is suggested
hat LC16m8 may protect humans from smallpox, if they
ere immunized with LC16m8 immediately after the event
f variola virus infection.
oi:10.1016/j.ijid.2008.05.022
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istribution and Genetic Diversity of Plasmodium fal-
iparum Erythrocyte Binding Antigen 175 and Clinical
utcome of Malaria in the Kassena-Nankana District
. Egyir ∗, C. Brown, M. Wilson, K. Koram
Noguchi Memorial Institute for Medical Research, Accra,
hana
The Erythrocyte Binding Antigen 175 (EBA 175) is a
75 kDalton Plasmodium falciparum antigen which plays a
ajor role in erythrocyte recognition by the parasite. It
lso induces antibodies which inhibit merozoite invasion.
BA 175 has been sequenced from FCR-3 and CAMP strains
f Plasmodium falciparum. The sequences were identical in
ost parts of the gene, differences were apparent in the
23bp segment in the FCR-3 strain, the F-genotype, and
he 342bp segment, the C-genotype. Parasite strains pos-
ess either one or the other segment and never both. The
unctions and potential effects of this dimorphism remain
nclear. This study therefore investigated the relationship
etween this dimorphism and clinical outcome of malaria.
nested polymerase chain reaction (PCR) was used to deter-
ine the genotypes of the parasite strains that exhibit this
imorphism in severe, mild and healthy controls of malaria
rom the Kassena Nankana District (KND), an area which
ad been earmarked for future vaccine trial. A total of 299
amples were analysed, 232 of these samples were positive
ith Plasmodium falciparum infections, these comprised 75
32.2%), 76 (32.6%) and 81 (35.5%) samples of severe, mild
nd healthy controls of malaria respectively, were geno-
yped for the EBA-175 gene. The severe samples, had a
istribution of 44 (58.66%), 24 (32%) and 7 (9.3%) of the
, C and CF EBA-175 genes respectively; the mild samples
omprised, 42 (55.3%), 29 (38%), and 5 (6.6%) of the F, C
nd CF EBA-175 genes respectively; the healthy controls:
9 (72%), 21 (26%), and 13 (16%) of the F, C and CF EBA-
75 genes respectively. A chi-square test revealed that the
ixed genotype (CF) is signiﬁcantly associated with severe
alaria (p = 0.04; OR = 8.23, 95% CI = 1.048—64.7), whereas
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he F genotype is signiﬁcantly associated with protection to
evere malaria (p = 0.045; OR = 0.909, 95% CI = 0.819—1.008).
he results therefore suggest that whilst the mixed geno-
ype CF EBA-175 is associated with malaria severity, the F
enotype of EBA-175 is protective.
oi:10.1016/j.ijid.2008.05.023
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ycobacterium avium KatG protein (MAV 2753): Possible
ole in the Pathogenesis of MAC disease
. Verma ∗, K. Gupta, G.K. Khuller
Postgradute Institute of Medical Education and Research,
handigarh, India
Background: The dissemination of Mycobacterium avium
omplex (MAC) disease could be due to certain mycobac-
erial factors causing cytotoxicity of host cells, thereby
eading to lysis of the cells and spreading of infection.
ecently, in our lab, an 82 kDa M. avium immunodominant
rotein was identiﬁed to be M. avium KatG homologue
MAV 2753). The BLAST search showed the N-terminal 40
mino acids of M. avium KatG to be 100% different from
he N-terminal of M. tuberculosis KatG. Present study was
esigned to explore the role of M. avium KatG protein in
he interaction with the host cells and its possible role in
he pathogenesis of MAC disease.
Methods: Organ speciﬁc (human alveolar macrophages
nd A549 lung epithelial cell line) and systemic cells (human
lood monocyte derived macrophages) were used to study
he interaction of M. avium KatG protein in terms of various
ytological, molecular and biochemical changes.
Results: M. avium KatG protein showed signiﬁcant bind-
ng with the host cells and resulted into signiﬁcant reduction
n the percent cellular viability (p < 0.001) thereby depicting
ts cytotoxic inﬂuence. The fragmentation of cellular DNA of
he KatG treated cells into smaller fragments demonstrat-
ng characteristic ‘ladder like pattern’ and the exposure of
hosphatidylserine on the outer leaﬂet of the plasma mem-
rane as represented by green halo and membrane blebbing
urther deﬁned these cytotoxic effects as apoptosis. The
poptosis of the host cells, as an effect of KatG protein was
ediated by ROS generation, caspase-3, caspase-7 and PARP
ctivation but not by TNF-alpha production. An increase in
he cellular viability following treatment with an antioxi-
ant, further conﬁrmed the role of ROS in KatG mediated
poptosis.
Conclusion: KatG protein of M. avium can bind to hostells, leading to their killing by apoptosis and might play a
ole in the cell to cell dissemination and pathogenesis of the
isease.
oi:10.1016/j.ijid.2008.05.024
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ostpartum Onset of HTLV-1-Associated Myelopa-
hy/Tropical Spastic Paraparesis (HAM/TSP): A Report of
Cases from Peru
. Ita1,∗, K. Verdonck2, E. Gonzlez1, E. Mayer1, E. Gotuzzo1
Instituto de Medicina Tropical ‘Alexander von Humboldt’,
niversidad Peruana Cayetano Heredia, Lima, Peru
Instituto de Medicina Tropical ‘Prncipe Leopoldo’,
mberes, Belgium
Background: HAM/TSP is a chronic progressive disease
hat causes impairment of the lower limbs and occurs in
—5% of HTLV-1 carriers. The disease affects women three
imes more frequently than men.
Methods: We describe 7 cases of women in whom
AM/TSP initiated within 6 months after delivery. They are
ll participants of the HTLV-1 cohort at the Institute of Trop-
cal Medicine Alexander von Humboldt in Lima. HAM/TSP
iagnosis was based on WHO criteria.
Results: The age at HAM/TSP onset ranged from 24—39
ears (mean: 31.4). The initial symptoms were noticed 3 to
6 weeks after delivery (mean: 8.8). Three of 6 women for
hom information was available developed HAM/TSP after
he birth of their ﬁrst child. Four women were of Andean
nd 3 of mestizo origin. None of the women reported a
amily history of HAM/TSP. Information about the initial
ymptoms was available for 6 women: 3 had lower limb
eakness, 2 reported sensory symptoms, and 1 woman had
rinary incontinence. During the course of disease, all devel-
ped the classic clinical presentation of HAM/TSP. Finally,
/7 presented rapidly progressive HAM/TSP, deﬁned as the
nability to walk unaided within 2 years after HAM/TSP
nset.
Conclusion: This is the ﬁrst report of several cases
f postpartum HAM/TSP. Several reports have shown that
AM/TSP patients have a higher proviral load than asymp-
omatic carriers. In one study, this difference was signiﬁcant
nly among women. It has also been described that clinical
rogression is faster in women than in men, especially in
re-menopausal women. We suggest that pregnancy could
ause a state of immunosuppression with diminished cyto-
oxic T-cell response, expansion of HTLV-1-infected cells,
nd increased proviral load. After delivery, the immune sys-
em returns to normality and the high proviral load might
ead to an intense inﬂammatory response in the central ner-
ous system causing HAM/TSP.
oi:10.1016/j.ijid.2008.05.025
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linico-Epidemiological Study of Pure Neural Leprosy
rom a Tertiary Hospital in Delhi, India
. Khandpur ∗, U. Kumar, B.K. Khaitan, N. KhannaAll India Institute of Medical Sciences, New Delhi, India
Background: Pure neural leprosy (PNL) continues to be
ommon in India. This form of disease is least studied and
ery little information exists in literature. We analyzed the
